Crohn's and Colitis Congress 2021

Virtual 21 January 2021 - 24 January 2021

Smoking effect on colorectal neoplasia risk may vary by IBD type

05 Feb 2021 by

The impact of cigarette smoke exposure on the risk of colorectal neoplasia (CRN) in patients with inflammatory bowel disease (IBD) may differ according to IBD type, suggested results of a single-centre study presented at the recent Crohn’s and Colitis Congress 2021.

Smoking effect on colorectal neoplasia risk may vary by IBD type

05 Feb 2021

Pre-op biologics not tied to post-op infection in IBD

02 Feb 2021 by

In patients undergoing surgery for inflammatory bowel disease (IBD), presurgical exposure to biologics was not associated with an increased risk of post-surgical infectious complications or surgical site infections, according to a study presented at the recent Crohn’s and Colitis Congress 2021.

Pre-op biologics not tied to post-op infection in IBD

02 Feb 2021

Ozanimod benefits UC by lowering inflammation markers in the gut

28 Jan 2021 by

One way the S1P* receptor modulator ozanimod reduces disease activity in patients with ulcerative colitis (UC) is by driving down biomarkers of intestinal inflammation such as faecal calprotectin (FCP) and faecal lactoferrin (FLF), according to the TOUCHSTONE study presented at the 2021 Crohn’s and Colitis Congress.

Ozanimod benefits UC by lowering inflammation markers in the gut

28 Jan 2021

Anti-TNF exposure may increase BMI in children with Crohn’s disease

28 Jan 2021 by

Exposure to anti-TNF therapy appears to be associated with an increased body mass index (BMI) z-score in paediatric patients with Crohn’s disease, according to a study presented at Crohn’s & Colitis Congress 2021.

Anti-TNF exposure may increase BMI in children with Crohn’s disease

28 Jan 2021

Amiselimod exhibits favourable safety in healthy individuals

27 Jan 2021 by

Amiselimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator, demonstrated a favourable safety profile among healthy individuals, according to a phase I study presented at Crohn’s and Colitis 2021.

Amiselimod exhibits favourable safety in healthy individuals

27 Jan 2021

IBD in kids: A protracted course?

26 Jan 2021 by

While children with inflammatory bowel disease (IBD) see their conditions improve with biologic therapy, those with ulcerative colitis (UC) tend to have residual disease activity even after clinical remission, according to two separate studies presented at the 2021 Crohn’s and Colitis Congress.

IBD in kids: A protracted course?

26 Jan 2021

Antibiotics improve disease activity in adults with Crohn’s disease

26 Jan 2021 by

A meta-analysis presented at Crohn’s and Colitis 2021 demonstrated reductions in disease activity among adults with Crohn’s disease (CD) who were taking antibiotics.

Antibiotics improve disease activity in adults with Crohn’s disease

26 Jan 2021